Sponsor-Backed IPOs From the Coverage Seat

Introduction

In a sale the sponsor negotiates with one buyer that wants control of the company. In an initial public offering (IPO) it sells to thousands of investors who each want a small piece and who know the largest holder will be back with more shares. That expectation shapes most of what is distinctive about a sponsor-backed IPO: why much of the money raised can go to the company's lenders rather than the fund, why board rights shrink with the stake, and why investors price the overhang of unsold shares into every offering. Medline shows the pattern. After its December 2025 listing, Blackstone, Carlyle and Hellman & Friedman (H&F) still held about 49% of the votes between them, and the group sold more stock twice within six months. Those follow-on offerings, rather than the listing, are where most of the funds' capital comes back, which is why a financial sponsors group (FSG) treats the IPO mandate as the first in a series that can run for years.

A listing is rarely the route that returns the most cash soonest. Sponsors choose it for what it provides besides cash: a public valuation for the shares they keep, a way to cut buyout debt without selling control, and, for the largest companies, access to a pool of buyers deeper than any single acquirer.

A Partial Exit That Prices the Remaining Stake

An IPO sells a minority of the company and leaves the sponsor holding the rest at a price the market sets every day. That suits a sponsor that believes the plan has further to run: it realizes part of the investment now, keeps the upside on the remainder, and gives its limited partners (LPs) a market mark they can check instead of a valuation the sponsor sets itself. A private minority sale to a new investor offers a similar split with one negotiated buyer and no listing.

Size pushes in the same direction. A company worth tens of billions has few strategic buyers that can pay for it and few sponsors that can finance it, while the public market can absorb it in pieces. The cost is time: only the shares sold at listing become cash, the rest following after the lock-up, often over two to three years, slower than each exit route's own calendar shows for a sale.

Deleveraging With Primary Proceeds

An offering can contain primary shares, newly issued with the cash going to the company, and secondary shares, sold by existing holders with the cash going to them. For a company carrying buyout leverage, primary proceeds that repay loans lower interest costs and make the equity story easier to sell, because public investors buy a less levered company than the sponsor owned.

Medline used the split in both directions. The proceeds of 179 million new shares bought units in its operating partnership, which used $731 million to repay its euro term loans in full and $3,292 million to repay part of its dollar term loans, according to Medline's quarterly report for the period to June 2026. The proceeds of the remaining 69.4 million shares, about $1.97 billion after underwriting discounts, bought existing interests from pre-IPO owners, the sponsors among them. How the offering itself was run, from confidential filing to pricing, is traced in the timeline of the IPO process itself.

That distinction decides how a sponsor reads its own IPO. The listing price sets the mark; the sell-down that follows produces the distributions.

A founder-led or carve-out IPO rarely needs the agreements a sponsor-backed one carries, because the sponsor remains a large holder with interests of its own. The prospectus therefore documents board rights, exit rights, tax arrangements and the fee relationships the sponsor keeps after listing.

Board Rights That Shrink With the Stake

Whether the company counts as controlled decides how far the sponsor can keep running the board.

Controlled Company Exemption

An exception in New York Stock Exchange and Nasdaq listing rules for a company in which an individual, a group or another company holds more than 50% of the voting power for the election of directors. Such a company may opt out of the requirements for a majority-independent board and fully independent compensation and nominating committees, while still needing an independent audit committee.

A single sponsor holding a majority after listing usually relies on the exemption. Medline did not use it: each sponsor held about 16.4% of the votes after the IPO and the founding Mills family about 17.8%, its voting capped at 20% under the charter, so no single holder had a majority. The board instead followed the normal phase-in to a majority of independent directors, and it found nine directors independent under Nasdaq standards, among them Blackstone's global head of private equity and H&F's chief executive.

Influence came through contract. Under separate director nomination agreements, each of the four main holders may designate a share of the board proportional to its stake, rounded up, while it owns at least 5%, and each planned to name two directors at listing; the three sponsors agreed to vote for the company's slate, according to Medline's IPO prospectus. A registration rights agreement gave the holders demand and piggyback rights, the same kind of exit term negotiated in the registration rights agreed during the hold.

Up-C Structures and the Tax Receivable Agreement

Companies owned through a partnership before listing often go public as an umbrella partnership C corporation (Up-C): public investors buy shares of a new corporation that owns units in the partnership, while pre-IPO holders keep units, with voting shares attached, and exchange them for listed shares when they sell. Each exchange can raise the tax basis of the partnership's assets, and a contract decides who keeps the savings.

Tax Receivable Agreement (TRA)

A contract under which a newly listed company pays some of its pre-IPO owners a fixed percentage of the tax savings it actually realizes from basis step-ups and other tax attributes created by the IPO structure, usually over a decade or more. The owners keep a stream of payments after selling their shares, and the company records a liability ahead of public shareholders.

Medline's agreement pays 90% of the realized benefits to certain pre-IPO owners. The prospectus estimated an aggregate liability of about $8,975 million, generally payable over 15 years, if every unit were exchanged at the $29 IPO price, and the company had recorded $4,404 million by June 2026. For the coverage banker the TRA is a second exit stream beside the share sales, and for public investors a claim that ranks ahead of them; the mechanics sit in the equity capital markets (ECM) guide's walk-through of Up-C economics.

Fees, Services Agreements and Affiliated Underwriters

Many portfolio companies pay their sponsors an annual fee for oversight, and some agreements accelerate the remaining years into a lump sum at a listing, a practice covered in the article on monitoring fees and fund economics. Medline's services agreements with its owners reimbursed out-of-pocket expenses rather than paying a fee, with Blackstone's entities receiving $784 thousand in the first nine months of 2025, and they continued after the IPO.

Sponsors with their own broker-dealers also take underwriting seats. Blackstone Securities Partners and Carlyle's TCG Capital Markets sat in Medline's syndicate, and because their affiliates owned more than 10% of the stock and received more than 5% of the net proceeds, both had a conflict of interest under the Financial Industry Regulatory Authority (FINRA) rule explained in the account of how sponsors allocate roles among their banks. No qualified independent underwriter was needed because the lead manager, Goldman Sachs, had no conflict.

On a sponsor-backed IPO the sponsor's deal partners sit beside the company's management when banks are chosen, and they judge the syndicate on the full sequence of offerings, not the first one. The coverage banker's leverage comes from the relationship and the bank's record with the company.

What the Sponsor Weighs When It Picks the Syndicate

Banks that financed the buyout, hold its loans and know its numbers start with an advantage, but a sponsor also weighs research credibility, distribution to the investors who will own the stock for years, and a bank's willingness to commit capital to later sales. Large sponsors add their in-house capital markets desks to the line-up. The coverage banker's work is to bring the bank's ECM, industry and leveraged finance teams to the sponsor as one view of the company, before and during a formal bake-off for the bookrunner roles. Medline's four global coordinators were Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan.

The IPO as the First of Several Mandates

The lock-up, under which the company, its directors and its pre-IPO owners agreed not to sell for 180 days after December 16, 2025, gave the lead banks a say over every early sale. Goldman Sachs and Morgan Stanley, as representatives of the IPO underwriters, released it for the March and May 2026 offerings, which the same four coordinators ran; how releases work is set out in the ECM guide's treatment of lock-up expiry.

The economics change along the way. Medline's IPO underwriting discount was about 2.18%, roughly $157 million in total, while the two follow-ons paid about 1.2% of their size, around $42 million and $34 million. Within six months of listing the syndicate had earned about half the IPO fee again, which is why banks compete for the follow-on calendar as hard as for the IPO, using the playbook for staged secondary offerings by sponsors.

Such a pitch also shows which banks expect to stay involved after the IPO fee is paid.

Distributions to paid-in capital (DPI), the ratio of cash returned to capital called, moves only when the fund sells shares or distributes them to its investors in kind. A listing changes the reported value of the stake; the sell-down converts it into cash.

The Overhang Investors Price In

Public investors know a sponsor holding a third or half of the shares will sell. They price that expected supply into the shares from the first day.

Share Overhang

The stock that large holders are expected to sell after an IPO, measured against the company's free float and trading volume. Investors treat it as future supply, which can weigh on the share price and widens the discount at which follow-on offerings must be priced.

The follow-on discount depends on demand on the day as much as on size. Medline's March 2026 offering priced at $41.00, about 4.4% below the previous close of $42.88, while the May offering priced at $37.00 against a close of $37.10. Sponsors manage the overhang through the size and spacing of sales, by selling alongside a company buyback, or by distributing shares to LPs in kind, and the wider choice between a listing and a sale is compared in the blog's guide to IPO, sale and recap exits.

Illustrative: How DPI Accrues Across a Sell-Down

Consider a fund that paid $1.0 billion for 100 million shares of a company that lists with the sponsor selling 10 million shares. The table follows the fund's cash and its cash back on cost over the next fifteen months, with prices net of discounts and fees.

Only about 8% of the stake's value is realized at the IPO, and the second follow-on, sold in a weak market, realized less per share than the first. The average realized price on the 80 million shares sold is about $28.60.

Bain singled out two private equity-backed IPOs of 2025, and they used the same tools in different proportions: Medline combined debt repayment with secondary sales in three steps, while Verisure raised new money and left its sponsor's stake largely intact.

Medline: A Consortium Selling in Installments

Medline's three sponsors bought a majority from the Mills family in 2021; GIC and a subsidiary of the Abu Dhabi Investment Authority (ADIA) also held stakes before the IPO. The prospectus tables show their combined voting power falling with each sale:

The May row assumes the underwriters' option went unexercised, as the company's later filing reports only the base shares. Carlyle sat out that offering, which was sold by affiliates of Blackstone and H&F and by ADIA's subsidiary, according to Medline's announcement of the May closing, so only Blackstone's broker-dealer carried a conflict of interest that time. The two follow-ons sold about $3.5 billion and $2.7 billion of stock. Each sponsor still held far more than the 5% needed to nominate directors, and the sell-down program was far from finished.

Verisure: A Listing Built on New Shares

Verisure, the monitored-alarm provider H&F has backed for about a decade, listed on Nasdaq Stockholm on October 8, 2025 at €13.25 a share, a market value of €13.7 billion. Almost all of the base offering was new shares, about €3.1 billion, with about €55 million sold by management shareholders, according to Verisure's pricing announcement. The sponsor's realization came mainly through the over-allotment option: about 33 million existing shares, sold by the holding vehicle owned by H&F, its co-investors and managers, and exercised in full later that month. Dealogic's ECM Pulse put H&F's retained stake at around 46%, free of the 180-day lock-up from April 2026.

Published tallies give each deal two sizes. Medline's base offering of 216.0 million shares raised about $6.26 billion and the full 248.4 million about $7.2 billion; Verisure's base deal raised about €3.2 billion and about €3.6 billion with the over-allotment, roughly $4.2 billion. Bain's 2026 global private equity report uses the larger figures, $7.2 billion and $4.2 billion.

Read side by side, the two deals put the sponsor's realization in different places. Medline paid down debt and bought out part of its owners at listing, then fed stock to the market in large follow-ons; Verisure used the listing mainly to raise new money, leaving most of H&F's exit for later. Both sponsors kept board seats and large economic stakes, and both left the market to price the shares still to come.

The progress of an exit like this can be read in the company's own filings. Each new prospectus shows smaller sponsor holdings in the ownership table, and the conflict-of-interest paragraph changes with the sellers: at Medline it named two affiliated underwriters in March and one in May. A sponsor-backed IPO is complete when the sponsors drop out of those pages, their holdings gone from the table, their nomination rights lapsed below 5% and no offering needing a conflict paragraph on their account. Until then the retained stake remains an open exit decision, weighed route by route in the exit pitch that compares routes for a mature asset, and the market keeps pricing the shares it expects to receive.